A-SKIN Nederland BV
De Boelelaan 1117
1081 HV Amsterdam
Website A-SKIN Nederland BV
E-mail A-SKIN Nederland BV
T +31 (0)20 444 26 24
F +31 (0)20 444 29 64

Employees in Amsterdam: 6
Employees in R&D: 3
Year of foundation: 2006

Company Profile

A-SKIN Nederland BV is a start-up from VUmc Amsterdam, and is positioned as a tissue engineering service company developing and commercialising autologous skin products from her GMP skin culture laboratory. Current customers are located in hospitals, out-patient clinics and (long term) care facilities in the Netherlands. In the coming years the patented A-SKIN autologous skin culture technique and related products will be made available trough out-licensing and daughter companies in other European countries and beyond.
With Tiscover® A-SKIN Nederland BV offers patients and professionals a novel and superior product for healing chronic, inert skin wounds. This product fills an unmet medical need in the treatment of various skin ulcers such as due to decubitus, diabetes or vascular malfunctioning.

Science and Technologies or Services

Alliances

• VU medical centre, Amsterdam
• Euro Skin Bank, Beverwijk
• Brandwonden centrum, Beverwijk

Keywords

• Tissue culturing
• Biomaterials
• Skin wounds
• Chronic leg ulcers
• Venous leg ulcers
• Decubitus ulcers
• Diabetic ulcers
  
  

P.O.Box 587
3440 AN Woerden
Website
E-mail
T +31 (0)6 5397 8750

Employees: 1
Employees in R&D: 1
Year of foundation: 2011

Company Profile

Abundnz is a privately owned spin-off company from Ducares, a TNO company. It was founded in October 2011. Abundnz offers advanced analytical support for biotechnology and diagnostics industries and life science research worldwide. With the use of mass spectrometry, we characterize innovative medicines like peptide and protein drugs, oligonucleotides and targeted drug delivery systems and we discover and validate biomarkers. Abundnz has a unique technology to determine the clearance profile of innovative medicines in an early phase of drug development.

Science and Technologies or Services

Abundnz has a service portfolio consisting of various analytical techniques and methods. Mass spectrometry and pAMS are our core technologies. With these techniques we contribute to innovative drug development, diagnostics and life sciences research.

Alliances

Biotech companies, universities

Keywords

• mass spectrometry
• innovative medicines
• protein drugs
• peptides
• oligonucleotides
• targeted drug delivery

Academic Medical Center (AMC)
Meibergdreef 9
1105 AZ Amsterdam
Website Academic Medical Center
E-mail Amsterdam Medical Center
T +31 (0)20 566 50 56
F +31 (0)20 566 91 68

Employees in Amsterdam: 6,500
Employees in R&D: 1,400
Year of foundation: 1983

Company Profile

Science and Technologies or Services

AMC is active in the following research fields:

• Cardiovascular Diseases
• Gastr-intestinal diseases
• Immunity and Infections
• Metabolic Disorders
• Neurologic and Psychiatric Disorders
• Oncology
• Public Health and Epidemiology

AMC also offers advanced facilities and highly qualified personnel in the areas of gene and cell therapies, viral vector production, genomics, proteomics, metabolomics, bioinformatics, imaging, and animal models.

Alliances

AMC spin-offs:

• AIMM Therapeutics
• AMCAS
• Amsterdam Molecular Therapeutics (AMT)
• Arthrogen
• Hep-Art Medical Devices
• IATEC
• Macrozyme
• MicroVision Medical
• Primagen
• Valletta Health

Keywords

• Academic hospital
• Medical research
• License opportunities
• Spin-off companies
  

AIMM Therapeutics B.V.
Meibergdreef 45
1105 BA Amsterdam
Website AIMM Therapeutics B.V.
E-mail AIMM Terapeutics B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 58

Employees in Amsterdam: 5
Employees in R&D: 5
Year of foundation: 2005

Company Profile

AIMM’s portfolio is based on proprietary platform technologies for directed, fast and efficient development of fully human monoclonal antibodies. Many innovative products for a wide range of viral and bacterial diseases as well as for cancer, are being developed.

Science and Technologies or Services

The goal is to isolate antibody-producing B cells from humans that have resolved a pathogenic challenge with high or exceptional efficiency. This would allow for the direct isolation of monoclonal antibodies with proven effectiveness in a clinical setting. Such proprietary B cell immortalization technologies for the selective isolation of human B cells shall lead to antibodies with desirable specificities.

Alliances

• AMC-Amsterdam;
• UMCU-Utrecht;
• NVI-Bilthoven.

Keywords

• Human antibodies;
• Vaccines.

AMCAS b.v.
Meibergdreef 45
1105 BA Amsterdam
Website AMCAS b.v.
E-mail AMCAS b.v.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 68

Employees in Amsterdam: 7
Employees in R&D: 5
Year of foundation: 2006

Company Profile

AMCAS is a world wide expert in exploiting an unique model with a human immune system in the fields of infectious diseases, auto-immune diseases and cancer. AMCAS offers this expertise to academic institutes and (bio)pharmaceutical industries.
AMCAS is located on the premises of the Academic Medical Center in Amsterdam, the Netherlands. AMCAS was initiated as a spin out company of this highly experienced scientific research center in the field of immunology and infectious diseases.
AMCAS provides fee-for-service pre-clinical studies using an unique model supporting the development of both the human innate and adaptive immune systems. The model can be manipulated to answer questions linked to developmental biology or treatment purposes (therapeutics and vaccines).

Science and Technologies or Services

AMCAS exploits a HIS(BALB-C-Rag₂^-/-cy^-/-) model (ref: J. Immunology 2006, 176: 2053-2058). This model shows a multi-lineage reconstitution in bone marrow and thymus with peripheral colonisation and development of functional human T-cells in situ.
AMCAS uses high standard facilities and employs or hires personnel with longstanding experience in operating standardised experiments.

Alliances

AMCAS is looking for fee-for-service projects upon assignment by customers having products in pre-clinical development in the field of biologics, vaccines and therapeutics having an anticipated (desired or side) effect on the immune system. Our HIS model can give the customer more detailed information on the anticipated effects of their development compounds on the human immune system in a validated best in class in vivo model.

ACE @ Science Park
Science Park 402
1098 XH Amsterdam
Website
E-mail
T +31 (0)20 525 79 52

Employees in Amsterdam: 3
Employees in R&D: 0
Year of foundation: 2007

Company profile

The City of Amsterdam is the national leader in its concentration of both scientists and research institutes. It is home to the science faculties and research institutes of the University of Amsterdam (UvA), the Vrije University (VU), the Academic Medical Centre (AMC) of the University of Amsterdam, the Medical Centre of the VU, and the institutes of the Netherlands Organisation for Scientific Research (NWO). The level of scientific and technological research is therefore world class.

Many research projects result in market-oriented innovations. This has a positive impact on the economy and society as a whole. However, the commercialization process whereby scientific innovations are brought to the market is still relatively undeveloped. Scientists lack entrepreneurial and business skills, whereas business people do not easily come into contact with the innovations originating from the research conducted at Science Park Amsterdam and the various scientific faculties.

Amsterdam Center for Entrepreneurship @ Science Park was established to foster education in entrepreneurship, stimulate and support innovative startups based on research done at Science Park Amsterdam institutes and at the Faculty of Science of the University of Amsterdam. ACE @ Science Park aims to attracts students, researchers, entrepreneurs, investors and companies to start and support new ventures at Science Park Amsterdam and become the ‘Amsterdam hub’ for science and technology entrepreneurship.

Science and Technologies or Services

Entrepreneurship education is offerd by the Faculty of Economics and Business by the University of Amsterdam Business School and by ACE @ Science Park. Entrepreneurship is offered for Bachelor, Masters and MBA students. In addition ACE @ Science Park offers workshops and seminars on science and technology entrepreneurship to faculty, Ph.D. and post-docs.

Alliances

• University of Amsterdam;
• Science park Amsterdam;
• Amsterdam Center for Entrepreneurship.

Keywords

• Entrepreneurship;
• Center of Entrepreneurship;
• Science Park Amsterdam;
• Education;
• Incubation;
• Valorisation;
• Research;
• Business;
• Technology.

Avantium Technologies B.V.
Zekeringstraat 29
1014 BV Amsterdam
Website Avantium Technologies B.V.
E-mail Avantium Technologies B.V.
Promotion video Avantium Technologies B.V.
T +31 (0)20 586 80 80
F +31 (0)20 586 80 85

Employees in Amsterdam: > 100
Year of foundation: 2000

Company Profile

Avantium is a leading technology company in the area of advanced high-throughput R&D operating in the energy, chemicals and pharmaceutical industries. The company develops products and processes in the area of biofuels, bio-based chemicals and novel crystal forms of existing drugs by applying its proprietary, high-throughput R&D technology.

Avantium has demonstrated the potential of this technology by providing R&D services and systems to more than 70 companies worldwide. Avantium's customer base includes many of the world's largest energy, chemicals and pharmaceutical companies, such as BP, Shell, Sasol, Pfizer and GSK. Avantium has more than 100 employees; its offices and head quarters are based in Amsterdam, the Netherlands.

Science and Technologies or Services

Avantium Solid State Research

Services
1. Finding the best polymorph, salt or co-crystal at any stage
2. Improving solubility with stable amorphous solid dispersions
3. Better protecting IP rights through comprehensive form identification
4. Developing robust crystallization processes
5. Crystal structure prediction

Crystalline New!
Visualizing, understanding and controlling the crystallization process.
This 5-ml crystallization platform with overhead stirring and refluxing capabilities provides real time particle size and shape information.

Crystal16
Speed up your crystallization research.
This benchtop 16 reactor crystallizer operates at less than 1-ml and is already used by all Top 20 Pharma companies.

Partnerships
- Develop novel crystal forms of marketed drugs
- In combination with alternative formulations
- Improve clinical or patient benefit and extend product life cycle

Delivering integrated solid state solutions.

Keywords

• High-throughput experimentation;
• Rational design;
• Polymorph screening;
• Salt selection studies;
• Co-crystallization screening;
• Crystallization process optimization;
• Enantiomer separation;
• Crystallization research;
• Crystal16™;
• Crystalline.

Piet Heinkade 183
1019 HC Amsterdam
Website
E-mail
T +31 (0)88 650 6500
F +31 (0)88 650 6555

Employees: 3
Employees in R&D: 0
Year of foundation: 2011

Company Profile

We focus entirely on the life sciences, together we have over 20 years of experience in the life science sector both as attorney at law and as in-house counsel.

Keywords

• law
• legal services
• coaching of high tech and life sciences start-up and spin-out companies

BioDetection Systems BV
Science Park 406
1098 XH Amsterdam
Website BioDetection Systems
E-mail BioDetection Systems
T +31 (0)20 435 07 50
F +31 (0)20 435 07 57

Employees in Amsterdam: 17
Employees in R&D: 10
Year of foundation: 2001

Company Profile

BDS is a hybrid-type biotech company, which was founded in 2001 as a spin off from the VU university Amsterdam. BDS is on the one hand an R&D-performing SME developing novel bio-based detection systems, using a functional genomics approach. On the other hand, BDS is and R&D end-user providing service analysis for food safety and environmental quality, and is licensing its technologies to over 40 (inter)national commercial and governmental laboratories in more than 20 different laboratories. BDS has an annual turnover of about 2 million Euros and runs a profit since 2005. BDS, has laboratories for R&D and for service analysis and is located in the high quality facilities of the Amsterdam Science Park at the kruislaan in the east of Amsterdam.

Science and Technologies or Services

Alliances

BDS has collaborative agreements with several allied parties mainly involving distributors and agents to help marketing its products globally. The institute for environmental studies of VU-University is an allied party with respect to analytical chemistry, in addition there are allied partnerships with several other knowledge institutes (WUR, NIOO, RIVM, TNO,KIWA, etc.) mainly within the framework of collaborative R&D projects.

Keywords

• Bioassays
• Fast screening methods
• Food safety
• Environmental quality
• Human monitoring
• (Eco)genomics
• CALUX^®
  
  
  

Bluelarix Designworks
Willem Fenengastraat 2W
1096 BN Amsterdam
Website Bluelarix Designworks 
E-mail Bluelarix Designworks
T +31 (0)20 820 22 11
F +31 (0)20 820 22 12

Employees in Amsterdam: 5
Employees in R&D: 5
Year of foundation: 2007

Company Profile

We specialize in designing products that make our lives safer, more interesting and easier. Our designs are logical, emotional, outspoken, simple and truely innovative.

Science and Technologies or Services

Medical product design, interaction design, engineering and product development services

Alliances

We work together with specialized electronics production companies with certifications for production and assembly of medical devices. We work together with hospitals and dokters in projects.

Keywords

• Medical design
• Product design
• interaction design
• Product development
• Electronics development
  

Bmeye B.V.
AMC, Suite K2-245
Meibergdreef 9
1105 AZ Amsterdam
Website Bmeye
E-mail Bmeye
Promotion video Bmeye
T +31 (0)20 566 58 38
F +31 (0)20 697 64 24

Employees in Amsterdam: 14
Employees in R&D: 8
Year of foundation: 2005

Company Profile

BMEYE is a technology-based company that develops innovative medical devices for the continuous non-invasive monitoring of blood pressure and cardiovascular hemodynamics.
Based on decades of fundamental technology and sensor research, BMEYE is committed to provide researchers, clinicians and patients worldwide with precise, robust, easy-to-use solutions for continuous, entirely non-invasive, cardiovascular monitoring
BMEYE Nexfin®monitors are designed for patient safety first: all measurements are completely non-invasive, with continuous data, no events are missed and with using our comfortable finger sensor, no needles, catheters or injections are needed. The precision of the Nexfin® sophisticated and robust methods provides a full hemodynamic profile with real-time data posted within a minute.

Science and Technologies or Services

Easy diagnosis, effective treatment
Patient responses to diagnostic cardiovascular tests, to interventional devices like pacemakers and to pharmacological treatment with drugs are highly variable and unpredictable, and are often composed of dynamic changes in blood pressure, vascular resistance, stroke volume and cardiac output. Today, their assessment is based on ECG measurements and intermittent standard upper arm NIBP cuff data that misses most if not all of the dynamics of the response.
Integrated continuous measurement of blood pressure and cardiac output in the BMEYE Nexfin® device allows easy and accurate diagnosis and effective follow-up of treatment, and provides the opportunity for immediate feedback to the patient on the effects of therapy and treatment.

Early warning, early and effective response
Patient response to anesthetic agents, cardiovascular drugs and surgical intervention is highly variable and unpredictable, and their combination often induces significant and rapid changes in blood pressure and cardiac output. During surgery, blood pressure monitoring, with the exception of less than 12% of patients who get direct intra-arterial blood pressure monitoring, is accomplished by using a standard cuff-based NIBP monitor, providing only intermittent measurements every 3-5 minutes. Cardiac output monitoring is even absent except in less than  4% of patients who receive pulmonary artery catheter CO monitoring.
Integrated continuous measurement of blood pressure and cardiac output allows early recognition and treatment of rapid changes in hemodynamics (where cardiac output changes usually lead blood pressure changes siginicantly in time) and provides immediate feedback on the impact of interventions for optimal patient management.

Unlike invasive A-lines and PA catheters, which carry a risk of infection or other complications, the BMEYE Nexfin® devices provide an integrated non-invasive solution for continuous blood pressure and cardiac output monitoring. In the OR today, blood pressure and cardiac output are the only critical parameters that are not monitored continuously on all patients. Heart rate, respiration and oxygenation are all monitored continuously and non-invasively for patient safety. The BMEYE Nexfin® technology allows truly complete, integrated and continuous non-invasive vital signs safety monitoring in all patients.

Alliances

• AMC, Amsterdam
• Mayo Clinic, Rochester, MN, USA

Keywords

• Cardiovascular
• Hemodynamics
• Patient Monitoring
• Noninvasive
• Continuous
• Safe
• Precise
• Easy-to-use
• Blood Pressure
• Cardiac Output

Zernikedreef 11
2333 CK Leiden
Website
E-mail
T +31 (0)71 518 8743
F +31 (0)71 518 8415

Employees: 6
Employees in R&D: 0
Year of foundation: 2007

Company Profile

CBD is a non-profit organization staffed by a small, dedicated group of lecturers affiliated to the Faculty of Technology in the University of Applied Sciences Leiden (Hogeschool Leiden). We possess a track record in successful postgraduate education of technical lab personnel, spanning over 20 years. Our main focus is to strengthen and modernize the theoretical and practical knowledge base of technical personnel involved in laboratory work in health care, pharmaceutical, industrial and forensic settings, thereby providing a secure basis for quality improvement. We also provide consultancy services for clients seeking to optimize lab tests and boost their quality assurance procedures.
Organisations who chose CBD for their schooling and training needs include VUmc, Crucell, Philips Healthcare Incubator, UMC Groningen, Naktuinbouw, Radboud University Medical Center, Vitens, Erasmus Medical Center and Heineken.

Science and Technologies or Services

CBD is active in the following areas of life science training and consultancy:

• Molecular biology/molecular diagnostics
• Microbiology/infectious diseases
• Immunology and immunochemistry
• Clinical chemistry and hematology
• Histology/pathology
• Agriculture/horticulture

CBD offers

• training courses for groups or individuals (at the University of Applied Sciences Leiden)
• incompany training trajectories, in which the course content is tailored to fit the schooling and quality improvement needs of the client
• consultancy services
• organization of conferences.

Alliances

• Toplab @ Hogeschool Leiden
• Naktuinbouw
• Boerhaave Nascholing, LUMC
• Symbiant

Keywords

• University of Applied Sciences Leiden
• life sciences
• postgraduate professional education
• in company training
• consultancy
• molecular biology/ molecular diagnostics
• microbiology/ infectious diseases
• immunology and immunochemistry
• clinical chemistry and hematology
• histology / pathology
• agriculture / horticulture

De Keijzer Nipius & Co
Paasheuvelweg 16
1105 BH Amsterdam
Website De Keijzer Nipius & Co
E-mail De Keijzer Nipius & Co
T +31 (0)20 564 60 00
F +31 (0)20 564 60 01

Employees in Amsterdam: 120
Employees in R&D: 0
Year of foundation: 1991

Company Profile

Mid-sized accounting, audit and tax firm offering a broad range of accounting, audit and tax compliance and tax advisory services. Well equiped to service all life science companies ranging from start ups and SME's to multinational listed companies. Our mid-size assures hands-on service with a focus on our clients needs.

Science and Technologies or Services

DEAM Corporation
Science Park 400
1098 XH Amsterdam
Website DEAM Corporation
E-mail DEAM Corporation
Promotion video DEAM Corporation
T +31 (0)20 717 3810
F +31 (0)84 225 29 63

Employees in Amsterdam: 3
Employees in R&D: 3
Year of foundation: 2005

Company Profile

DEAM develops and manufactures instruments for minimally invasive therapies.

Science and Technologies or Services

DEAM has extensive knowledge on steering technology for use in instruments for minimally invasive therapies. It has an own patent database covering an unique steering mechanism that can be used in rigid or flexible instruments having diameters ranging from 0,5 to 11 mm.
DEAM develops and manufactures steerable instruments on their own or on customer demand.
Current product development is focussed on instruments for laparoscopic procedures, cardiology and eye surgery.

Alliances

Keywords

• Steerable
• Surgical
• Instrument
• Minimally
• Invasive
  
  

DUCARES B.V.
P.O. Box 360
3700 AJ Zeist
Website DUCARES B.V.
E-mail DUCARES B.V.
T +31 (0)88 382 27 37
F +31 (0)88 382 27 00

Employees in Amsterdam: 19
Employees in R&D: 10
Year of foundation: 2008

Company Profile

DUCARES B.V. offers its customers a wide range of analytical solutions varying from standard accredited methods to advanced analytical solutions.
Since many years DUCARES serves (inter)national companies, industries and governmental institutes in the areas of:

• Pharma;
• Chemistry;
• Food and Food Safety;
• Feed;
• Primary agricultural sectors;
• Environment;
• Non-food.

Keywords

• Analytical research;
• Bioanalysis;
• Pharmaceutical analysis.